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Background. Acute kidney injury (AKI) is a common and severe complication in patients with cirrhosis. Progression of AKI to
a higher stage associates with increased mortality. Intervening early in AKI when renal dysfunction is worsening may improve
outcomes. However, serum creatinine correlates poorly with glomerular filtration in patients with cirrhosis and fluctuations may
mask progression early in the course of AKI. Cystatin C, a low-molecular-weight cysteine proteinase inhibitor, is a potentially
more accurate marker of glomerular filtration. Methods. We conducted a prospective multicenter study in patients with cirrhosis
comparing changes in cystatin and creatinine immediately following onset of AKI as predictors of a composite endpoint of dialysis
or mortality. Results. Of 106 patients, 37 (35%) met the endpoint. Cystatin demonstrated less variability between samples than
creatinine. Patients were stratified into four groups reflecting changes in creatinine and cystatin: both unchanged or decreased
38 (36%) (Scr−/CysC−); only cystatin increased 25 (24%) (Scr−/CysC+); only creatinine increased 15 (14%) (Scr+/CysC−); and
both increased 28 (26%) (Scr+/CysC+). With Scr−/CysC− as the reference, in both instances where cystatin rose, Scr−/CysC+
and Scr+/CysC+, the primary outcome was significantly more frequent in multivariate analysis, 𝑃 = 0.02 and 0.03, respectively.
However, when only creatinine rose, outcomes were similar to the reference group. Conclusions. Changes in cystatin levels early
in AKI are more closely associated with eventual dialysis or mortality than creatinine and may allow more rapid identification of
patients at risk for adverse outcomes.
1. Introduction
Acute kidney injury (AKI) is a common complication in
patients with cirrhosis and associates with higher mortality
in proportion to progressive AKI severity [1, 2]. However, the
most common indicator of renal function, serum creatinine,
may be an unreliable surrogate for glomerular filtration rate
(GFR) due to the impact of nonrenal determinants such as
sex, race, age, body composition, andmedications. In the set-
ting of an acute drop in GFR, creatinine is insensitive to small
decrements in function, and its rise can lag actual kidney
injury by several days. These shortcomings of creatinine are
magnified in patients with cirrhosis, as they have an enlarged
volume of fluid distribution and decreased creatinine pro-
duction secondary to muscle atrophy and liver dysfunction,
further dissociating creatinine from GFR [3]. The accuracy
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of creatinine in reflecting GFR declines with worsening
stages of cirrhosis [4] and can be further compromised by
elevated bilirubin interfering with creatinine assays [5]. We
have previously shown that progression of AKI associates
with mortality [6]. However, progression of AKI to a higher
creatinine defined stage may be delayed in the setting of
cirrhosis due to early fluctuation in creatinine levels unrelated
to renal function and potentially beneficial treatments may
resultantly be deferred. A more accurate means of rapidly
and accurately detecting changes in renal function early in
the course of AKI that associate with outcomes may allow for
more prompt initiation of therapy and improved outcomes.
Cystatin C is a low-molecular-weight cysteine proteinase
inhibitor synthesized at a constant rate by all nucleated cells.
Cystatin C is freely filtered by the glomerulus, nearly com-
pletely reabsorbed and catabolized by the proximal tubule,
and does not undergo secretion. Cystatin C levels are less
influenced by nonrenal factors than creatinine and it has thus
been proposed as a superior marker of glomerular filtration.
In AKI, cystatin rises more rapidly than creatinine in some
settings and has been shown to associate more strongly with
outcomes. Cystatin performs better than creatinine in early
detection of AKI in the emergency room [7], intensive care
unit (ICU) [8, 9], and following pediatric cardiac surgery
[10]. Cystatin associates with duration of AKI [11], need for
renal replacement therapy [8, 12], and short and long term
mortality in AKI [12, 13]. Patients who experience increases
in both cystatin C and creatinine experience worse outcomes
than those with an increase in either marker alone [14, 15].
In patients with cirrhosis, cystatin C has been shown to more
accurately correlate with measured GFR than creatinine or
creatinine based estimation equations [16]. Cystatin C is also
more sensitive than creatinine in cirrhotics for detectingmild
decreases in baseline GFR [17, 18] and superior in predicting
AKI or 3-month mortality [19]. Despite these attributes,
cystatin C has been challenging to study in patients with
cirrhosis and AKI due to the typical lack of a documented
baseline value. The absence of a baseline renders cystatin
ineffectual in practice for diagnosing AKI prior to creatinine
as there is no value to compare to for assessment of absolute
or relative changes. However, due to its lesser dependence
on nonrenal determinants, small changes in cystatin levels
early in the course of AKI may be more reflective of true
trends in renal function than those of creatinine, whichmight
continue to oscillate for several days before displaying a clear
trend towards renal worsening or recovery. An alternative
study design therefore is comparing trends in cystatin C and
creatinine levels immediately following the onset of clinical
apparent AKI to evaluate the relative utility of early fluctua-
tions in each marker in predicting outcomes following AKI.
We conducted a prospective multicenter study in patients
with cirrhosis comparing changes in cystatinC and creatinine
immediately following onset of AKI as predictors of dialysis
and mortality during this early time period.
2. Subjects and Methods
2.1. Study Design. The details of the cohort of patients with
cirrhosis and AKI and study design have been described
previously [6]. This prospective, multicenter observational
cohort study was conducted between 2009 and 2011 at four
tertiary care academic centers in the USA. Eligible patients
were admitted with AKI (see “Section 2.3”) or developed
it during the course of hospitalization. Inclusion criteria
included a known diagnosis of cirrhosis (see “Section 2.3.1”),
age ≥ 18 years, and availability of documented serum creati-
nine within 1 year prior to AKI. Exclusion criteria included
prior kidney or liver transplant, advanced chronic kidney
disease (CKD) (baseline creatinine >4.0mg/dL), acute or
chronic renal replacement therapy at enrollment, estimated
life expectancy <3 days, confirmed pregnancy, and other
known causes of renal insufficiency such as glomerulonephri-
tis or urinary obstruction. Informed consent was obtained
from all participants or, if patients were unable to provide
consent, from designated surrogates. All consecutive eligible
patients identified during screening were approached for
enrollment and all participants were enrolled within 5 days
of meeting AKI criteria. The study was approved by the
institutional review board at each institution.
2.2. Sample Collection and Biomarker Measurement. A fresh
10mL blood sample was collected daily for three days follow-
ing the onset of AKI. Samples were immediately refrigerated
and then centrifuged at 5000×g for 10 minutes at −4∘C.
Aliquots of 1mL of supernatant were subsequently stored
within 6 hours of collection in cryovials at −80∘C for
cystatin C measurement. No additives or protease inhibitors
were utilized. Measurement was performed on subsequently
thawed aliquots without undergoing any additional freeze-
thaw cycles. Cystatin C was measured using a BN II neph-
elometer (Siemens AG, http://www.siemens.com/), which
has an approximate coefficient of variation of 2% [20].
Creatinine was measured from samples collected as part of
routine clinical care via the modified Jaffe method. Labora-
tory measurements were performed by personnel blinded to
patient information.
2.3. Definitions
2.3.1. Independent Variables
Cirrhosis. Patients who were eligible carried an existing
documented diagnosis of cirrhosis based on liver biopsy,
when available, or a combination of clinical, biochemical,
ultrasonographic, and endoscopic findings.
AKI. The acute kidney injury network (AKIN) criteria were
applied for diagnosis of AKI as recommended by a working
group composed of members of the International Ascites
Club (IAC) and the Acute Dialysis Quality Initiative (ADQI)
[21]. AKIN quantifies the severity of AKI based on degree
of increase in serum creatinine relative to baseline and is
defined as follows: stage 1, increase in creatinine by 0.3mg/dL
or 50%; stage 2, 2- to 3-fold increase; stage 3, >3-fold increase,
or creatinine >4.0mg/dL after a rise of at least 0.5mg/dL or
acute dialysis requirement. As urine collection and output
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documentation can be inconsistent, only the serum creati-
nine component of the AKIN criteria was utilized.
Baseline Serum Creatinine. Baseline serum creatinine was
defined as the most recent stable measurement within a year
prior to admission for the index hospitalization. When pos-
sible, outpatient measurements were utilized though values
were also used from previous admissions not complicated by
AKI. In rare cases, patients without an outpatient measure-
ment were included in the analytic cohort if, prior to onset
of AKI, they manifested at least 5 initial days from admission
of stable values within the normal creatinine range. In these
instances, the creatinine at admission was considered the
baseline.
Other Variables. When calculating between-sample percent
change in creatinine and cystatin C, the first and last available
samples were utilized. GFR was estimated via the CKD-EPI
equation using the baseline creatinine value [22]. CKD was
defined by as GFR < 60mL/min. MELD and Child-Pugh
scores were calculated on the day of first sample collection.
Outcomes. Our primary outcome was a composite of dialysis
and in-hospital mortality during the index hospitalization.
2.4. Statistics. Categorical variables were expressed as pro-
portions and compared using Chi-square and Fisher’s exact
test, as appropriate. Normally or near normally distributed
variables were reported as means with standard deviations
(SD) and compared by Student’s t-test. Nonnormally dis-
tributed continuous variables were reported as medians with
interquartile ranges (IQR) and compared by Wilcoxon rank
sum test. Normality was assessed using the Kolmogorov-
Smirnov test. Correlation between the percentage change
between samples of creatinine and cystatin Cwas assessed via
Pearson’s test.
Patients were categorized into four groups based on
trends between the first and last sample of two filtration
biomarkers, serum creatinine, and serum cystatin C. The
groupswerewhen (1) both biomarkers fell or were unchanged
(2) only serum creatinine exhibited any increase (3) only
serum cystatin C increased and (4) both increased. Only
serum creatinine exhibited any increase, only serum cystatin
C increased, and both increased. As our intent was to
compare the association between small, early changes in
filtration markers with outcomes, no threshold was utilized
as to what constituted an increase. With the group with
both biomarkers unchanged or falling as the reference, we
determined crude and adjusted relative risks of each other
group for our composite primary outcome with multivariate
modified Poisson regression using SAS PROC GENMOD.
Adjustment was made for critical demographics variables
associatedwith filtrationmarkers including race, age, and sex.
Goodness-of-fit was verified with the Hosmer-Lemeshow
test. A 2-sided 𝑃 < 0.05 was considered significant for all
analysis. Statistical analysiswas performedusing SAS, version
9.2 (SAS Institute, Cary, NC).
3. Results
A total of 192 patients were enrolled in our cohort with
cirrhosis and AKI. Of these, 106 had at least 2 blood
samples collected and were included in this study. Samples
were not collected in the remaining 86 patients either due
to failure to consent to blood collection or initiation of
dialysis prior to obtaining consent. Baseline demographic,
clinical, and laboratory characteristics for the entirety of
study participants and the four groups designated by trends
in creatinine and cystatin C are shown in Table 1. There were
no significant differences in any demographic variables or
in those relating to the patients’ liver disease between those
patients who did and did not have serum samples collected.
The mean patient age was 56.3 and 66% were male. Thirty-
seven (35%) patients met the primary composite endpoint
during their hospitalization. Of these, 28 patients died and 22
required dialysis, with 13 of these experiencing both dialysis
and death. On sensitivity analysis, there was no difference in
death, 28/106 (26%) versus 22/86 (26%), or the composite of
death or dialysis, 37/106 (35%) versus 30/86 (35%), between
those patients with and without blood samples obtained.
The majority of patients had advanced cirrhosis evidenced
by previously suffered complications including ascites, 76%,
hepatic encephalopathy, 63%, variceal bleeding, 23%, and
SBP, 12%. Reasons for admission were similar between the
four groups.Themedian Child-Pugh score was 10 andMELD
26.4 at the time of enrollment. There was no difference in
Child-Pugh andMELD scores across groups nor were serum
sodium levels or the presence of hyponatremia at enrollment
significantly different.
3.1. Biomarkers and Prognosis. Three blood samples were
collected in 77 (73%) patients, and two were collected in
the remainder, 29 (27%). The first sample was collected at a
median of 2 (IQR 2–4) days after first meeting AKIN criteria.
While creatinine and cystatin C levels from the first sample
were moderately correlated, 𝑟2 = 0.55, the relative changes
in creatinine and cystatin C values between the first and last
sample were less, so, 𝑟2 = 0.3, 𝑃 < 0.0001. Correlations
between creatinine and cystatin C levels in the initial samples
and between relative and absolute changes in each filtration
marker between samples are shown in Figures 1(a), 1(b), and
1(c), respectively. CystatinC exhibited less variability between
samples than seen with creatinine with the interquartile
range for percent change in creatinine ranging from −17 to
+11% compared with cystatin C ranging from −9 to +12%.
A change of <10% was observed in 35/106 (33%) patients
by creatinine and 53/106 (50%) patients based on cystatin
C (𝑃 = 0.018). The median change in cystatin C values
differed significantly between those patients with the primary
outcome, +6% (95% CI −2 to +14%), and those without, −3%
(−9 to +9%),𝑃 = 0.03.The difference in changes in creatinine
for those with and without the primary outcome trended in
the same direction but did not reach statistical significance,
0% (−12 to +17%) versus −5% (−21 to +8%), 𝑃 = 0.07.
Patients experiencing an increase in cystatin C levels between
samples were significantly more likely to meet the primary
4 International Journal of Nephrology
Table 1: Baseline demographic, clinical, and laboratory values.
Total Scr−/CysC− Scr−/CysC+ Scr+/CysC− Scr+/CysC+
𝑃
𝑁 = 106 𝑁 = 38 𝑁 = 25 𝑁 = 15 𝑁 = 28
Age in years, mean ± SD 56.3 ± 8.9 54.6 ± 9.8 57.1 ± 10.2 58.1 56.9 0.52
Male sex, 𝑛 (%) 70 (66) 26 (68) 17 (68) 8 (53) 19 (68) 0.74
BMI, median (IQR) 30.6 (25.7–36) 32.2 (26.3–36.8) 29.2 (25.5–32.6) 33.2 (25.7–21.3) 31.5 (25–36.5) 0.41
Race, 𝑛 (%)
White 76 (72) 30 (79) 17 (68) 12 (80) 17 (61) 0.34
Black 16 (15) 4 (11) 4 (16) 2 (13) 6 (21) 0.67
Hispanic 12 (11) 4 (11) 3 (12) 1 (7) 4 (14) 0.90
Diabetes, 𝑛 (%) 24 (23) 12 (32) 2 (8) 3 (20) 7 (25) 0.16
Active cancer, 𝑛 (%) 13 (12) 5 (13) 2 (8) 2 (13) 4 (14) 0.92
Baseline creatinine mg/dL, median (IQR) 1.02 (0.8–1.3) 1 (0.8–1.2) 0.97 (0.8–1.2) 1.1 (0.9–1.43) 1.18 (0.8–1.56) 0.12
CKDa 34 (32) 9 (24) 8 (32) 6 (40) 11 (39) 0.51
Cirrhosis etiology, 𝑛 (%)
Alcohol 32 (30) 11 (29) 12 (38) 4 (27) 5 (18) 0.13
Alcohol and HCV 27 (25) 13 (34) 3 (12) 1 (7) 10 (36) 0.04
HCV 19 (18) 6 (16) 3 (12) 2 (13) 8 (29) 0.45
NASH 10 (9) 2 (5) 2 (8) 3 (20) 3 (11) 0.40
Cryptogenic 4 (4) 1 (3) 1 (4) 2 (13) 0 (0) 0.16
Autoimmune 7 (7) 3 (8) 2 (8) 2 (13) 0 (0) 0.28
Other 8 (8) 3 (8) 2 (8) 2 (13) 1 (4) 0.65
Previous complications of cirrhosis, 𝑛 (%)
Ascites 81 (76) 27 (71) 21 (84) 11 (73) 22 (79) 0.67
Hepatic encephalopathy 67 (63) 22 (58) 15 (60) 11 (73) 19 (68) 0.68
Variceal bleed 24 (23) 12 (32) 5 (20) 3 (20) 4 (14) 0.42
SBP 12 (12) 3 (8) 5 (20) 2 (13) 4 (14) 0.55
Reason for admission, 𝑛 (%)
Hepatic encephalopathy 26 (25) 10 (26) 4 (16) 5 (33) 7 (25) 0.63
Refractory ascites/edema 16 (15) 6 (16) 4 (16) 3 (20) 3 (11) 0.86
AKI 12 (11) 3 (8) 2 (8) 2 (13) 5 (18) 0.60
GI bleed 8 (8) 3 (8) 1 (4) 0 (0) 4 (14) 0.44
Abdominal pain 7 (7) 4 (11) 1 (4) 1 (7) 1 (4) 0.78
Jaundice 5 (5) 3 (8) 1 (4) 1 (7) 0 (0) 0.50
Transplant work-up 6 (6) 1 (3) 2 (8) 1 (7) 2 (7) 0.70
SBP 4 (4) 0 (0) 2 (8) 0 (0) 2 (7) 0.20
Infection other than SBP 4 (4) 2 (5) 1 (4) 1 (7) 0 (0) 0.57
Other 20 (19) 7 (18) 7 (28) 2 (13) 4 (14) 0.63
Child-Pugh Classb,𝑛 (%) 0.17
B 37 (35) 17 (45) 6 (24) 7 (47) 7 (25)
C 69 (65) 21 (55) 19 (76) 8 (53) 21 (75)
Child-Pugh score, median (IQR) 10 (9–12) 10 (9–12) 11 (10–12) 10 (8–12) 10 (10–12) 0.39
MELD score, mean ± SD 26.4 ± 9.5 25 ± 9 26.8 ± 9.8 23.8 ± 7.4 29.3 ± 10.5 0.20
Bilirubin, median (IQR) 4 (1.8–9.1) 3 (1.6–6.4) 6.1 (2.6–9.6) 3.8 (1.6–5.5) 5.5 (2–16.7) 0.31
INR, median (IQR) 1.7 (1.3–2.3) 1.5 (1.2–2.3) 1.8 (1.4–2.3) 1.6 (1.2–1.8) 1.9 (1.4–2.7) 0.08
Sodium, mean ± SD 133 ± 6 133 ± 6 132 ± 7 135 ± 7 133 ± 7 0.74
Hyponatremia at enrollmentc,𝑛 (%) 34 (32) 12 (32) 10 (40) 5 (33) 7 (25) 0.71
aCKD defined as GFR < 60mL/min calculated via CKD-EPI equation.
bChild-Pugh Class and MELD score at time of enrollment.
cSerum sodium <130mEq/L.
SD: standard deviation; BMI: body mass index; IQR: interquartile range; CKD: chronic kidney disease; HCV: hepatitis C virus; NASH: nonalcoholic
steatohepatitis; SBP: spontaneous bacterial peritonitis; MELD: model of end-stage liver disease; INR: international normalized ratio.
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Figure 1: Correlation between creatinine and cystatin. (a) Correlation between creatinine and cystatin C values from first sample collection.
(b) Correlation between relative changes in creatinine and cystatin C values from first to last sample collection. (c) Correlation between
absolute changes in creatinine and cystatin C values from first to last sample collection.
Table 2: Association between increasing filtration markers and the
primary outcome.
Death/dialysis,
𝑁 (%)
Dialysis-free
survival,𝑁 (%) 𝑃
Creatinine
Increase (𝑁 = 43) 17 (40) 26 (60) 0.41
No increase (𝑁 = 63) 20 (32) 43 (68)
Cystatin C
Increase (𝑁 = 53) 25 (47) 28 (53) 0.008
No increase (𝑁 = 53) 12 (23) 41 (77)
endpoint, 47%, than those without such an increase, 23%,
𝑃 = 0.008. However, there was no significant difference in
the incidence of dialysis or mortality among those whose
creatinine increased, 40%, than among thosewhere it did not,
32%, 𝑃 = 0.41 (Table 2). Neither the cystatin C nor creatinine
values from the first sample collected showed any association
with the primary outcome.
Patients were stratified into four mutually exclusive
groups based on changes in creatinine and cystatin C:
both unchanged or decreased 38 (36%) (Scr−/CysC−); only
cystatin C increased 25 (24%) (Scr−/CysC+); only creatinine
increased 15 (14%) (Scr+/CysC−); and both creatinine and
cystatin C increased 28 (26%) (Scr+/CysC+). The incidence
of dialysis or death for each group is shown in Table 3. Taking
the Scr−/CysC− group as the reference, in both instances
where cystatin C rose, Scr−/CysC+ and Scr+/CysC+, the
occurrence of the primary outcome was significantly higher,
𝑃 = 0.02 and 0.03, respectively. However, in the group
where only creatinine rose, outcomes were similar to the
reference group. Both the Scr−/CysC+ and Scr+/CysC+ but
not Scr+/CysC− groups were associated with a significantly
increased relative risk for the primary outcome in unadjusted
analysis as well as after adjustment for age, race, and sex.
4. Discussion
AKI in patients with cirrhosis is often severe and associated
with significant mortality risk. Potentially efficacious ther-
apies exist but must be appropriately applied to patients at
highest risk for adverse outcomes [23]. We have demon-
strated that progression to a more advanced stage of AKI is
independently associated with mortality but the likelihood
of progression can be difficult to predict early in the course
of AKI. Creatinine levels are dependent on multiple demo-
graphic and clinical factors beyond renal function and thus
may be susceptible to short term fluctuations early in the
6 International Journal of Nephrology
Table 3: Independent association of trends in filtration markers and the primary outcome.
Death or dialysis,𝑁 (%) Death or dialysis
Unadjusted RR (95% CI) Adjusted∗ RR (95% CI)
Scr−/CysC− (𝑁 = 38) 8 (21) 1.00 1.00
Scr−/CysC+ (𝑁 = 25) 12 (48) 2.28 (1.09–4.77) 2.27 (1.07–4.85)
Scr+/CysC− (𝑁 = 15) 4 (27) 1.27 (0.45–3.59) 1.32 (0.46–3.75)
Scr+/CysC+ (𝑁 = 28) 13 (46) 2.21 (1.06–4.59) 2.17 (1.03–4.61)
∗Adjusted for race, age, and sex.
course of AKI unrelated to changing GFR [3, 24]. Cirrhosis
potentiates these shortcomings of creatinine due to associated
low protein intake, reducedmuscle mass, defective creatinine
production, and frequent large fluid shifts. In patients with
cirrhosis, creatinine based estimation of GFR is within 50%
of measured values in only 9% of patients [25]. Cystatin C
has been proposed as a biomarker of glomerular filtration less
susceptible to extrarenal variation. In patients with cirrhosis,
GFR estimates are less biased and more precise with cystatin
C than creatinine [25, 26]. Cystatin levels, but not creatinine,
are associated in cirrhotic patients with development of AKI
and mortality over a 3–6-month period [19] and the onset
of hepatorenal syndrome and mortality at one year [27].
The purpose of this study was to compare the association of
changes in cystatin C and creatinine early in the course of
AKI in patients with cirrhosis with a composite outcome of
dialysis or death.
In our study, changes in cystatin C, but not creatinine,
over the period of sample collection differed significantly for
those with and without the primary outcome. Participants
experiencing a rise in cystatin C alone (Scr−/CysC+) between
samples progressed to the need for dialysis or death at the
same rate as those with a rise in both biomarkers of filtration
(Scr+/CysC+). However, those with a rise in creatinine alone
(Scr+/CysC−) experienced the primary outcome with no
greater frequency than those in whom both biomarkers fell
(Scr−/CysC−). Relative to the group in which both markers
fell, both groups with rising cystatin were independently
associated with the primary outcome.The lack of association
between rising creatinine and our primary endpoint stands
in contrast to our previous demonstration of a strong asso-
ciation between progression of AKI to a higher creatinine
defined stage and mortality [6]. This discrepancy is again
evidence of the poor sensitivity of creatinine for detecting
acute falls in renal filtration function. Given its extrarenal
influences and the extent to which changes in levels lag falling
GFR, creatinine rising over the entire duration of an AKI
episode sufficient to qualify for a higher AKI stage is indeed
specific for a significant fall in renal function and resultantly
associates with poor outcomes. Over the short term, however,
early in the course of AKI, creatinine changes need not reflect
trends in renal function and thus show poor association with
outcomes when not coupled with similar changes in cystatin
C levels.
Cystatin C strongly associates with outcomes in multiple
settings of AKI including ICU9, emergency room [7], and
transplant [28]. Intriguingly, changes in cystatin C may be
more specific to outcomes than creatinine. Kwon et al. studied
274 ICU patients, of whom 84 (30.7%) developed AKI [29].
The mortality in patients with acute elevation in cystatin
C but without creatinine based AKI (28.6%) was similar to
patients with AKIN stage 1 AKI (33.3%) and far outstripped
that of patients with no elevations in either biomarker
(5.7%). This finding mirrors the results of our study with
poor outcomes in patients with Scr−/Cys+. The apparent
prognostic advantage of cystatin C may be due to its ability
to more accurately reflect early/small changes in GFR due
to fewer nonrenal influences. Early in AKI, before GFR has
undergone a truly dramatic fall, creatinine may be subject to
greater fluctuations than cystatin C, fluctuations untethered
from changes in GFR. In our study, creatinine and cystatin
C levels exhibited good correlation at time of first sample
collection, 𝑟2 = 0.55. However, the correlation between
changes in thesemarkers over the course of sample collection
was significantly lower, 𝑟2 = 0.3. Changes in cystatin C levels
during the period of sample collection were more tightly
bunched than those of creatinine. Cystatin C demonstrated
less variability with a smaller interquartile range for changes
and a significantly higher number of patients with a change
of <10%.
In addition to being more specific for early changes in
GFR than creatinine, cystatin C may also be more sensitive.
The superiority of cystatin C over creatinine for detecting
early acute changes in renal function has been noted in
multiple settings. Herget-Rosenthal et al. performed daily
serum collections on 85 ICU patients deemed high risk of
developing AKI [8]. In the 44 (52%) patients who developed
AKI as defined by the risk, injury, failure, loss, and end-stage
(RIFLE) criteria, cystatin C levels detected AKI (defined by
a 50% increase from baseline) 1.5 ± 0.6 days earlier than
serum creatinine. Similar results have been noted in the ICU
[8, 9], following iodinated contrast [30] and postoperatively
in pediatric [10], though not adult [15], cardiac surgery.
Our study has several significant strengths. Data were
collected prospectively for what is, in this challenging study
population, a large cohort of patients. Unlike many studies
of cirrhosis and AKI, ours was multicenter and contained
patients from both general medical floors and the ICU,
enhancing its generalizability. However, the study is not
without limitations. Cystatin C can be influenced by several
nonrenal factors including steroids and thyroid function.
While we do not have data for these variables, it is reassuring
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that none of the baseline and demographic variables in
Table 1 predicted which of the four groups patients would
assort into. This is especially true for cirrhosis etiology,
where the potential use of steroids to treat acute hepatitis
in alcohol related cirrhosis did not dictate the pattern of
changes in cystatin C. However, we cannot definitively rule
out that changes in cystatin may be reflecting some other
physiologic processes in addition to renal functions that may
be contributing to the primary outcome.Wedid not have data
on baseline cystatin C levels and patients were enrolled based
on creatinine defined AKI. This raises a concern that the
results could be biased for patients whose creatinine fell due
to regression to the mean. However, the lack of association
between enrollment cystatin and creatinine values and the
primary outcome assuages this concern.
In conclusion, changes in serum cystatin C early in
the course of AKI in patients with cirrhosis associate more
strongly with the need for dialysis and mortality than do
changes in serum creatinine. Prospective trials indexing
interventions to changes in cystatin are required to determine
if routine monitoring of cystatin C in patients with cirrhosis
and AKI may lead to improved outcomes.
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